NCT04221451: An ongoing trial by Genzyme, a Sanofi Company
This trial is ongoing. It must report results 1 week, 3 days from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04221451 |
|---|---|
| Title | A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 29, 2020 |
| Completion date | Dec. 26, 2024 |
| Required reporting date | Dec. 26, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |